A Long-term Follow-up Study to Evaluate the Injection of EXG102-031 Ophthalmic Injection in Participants With Wet Age-related Macular Degeneration (wAMD)

What this Trial Is About

Researchers are evaluating the long-term safety and efficacy of EXG102-031 ophthalmic injection in patients with wet age-related macular degeneration (wAMD) who have previously received this gene therapy treatment. This study focuses on monitoring patients over several years to understand any lasting effects and safety concerns after the initial treatment. Participants in this observational study will continue visits from the parent EXG102-031-111 clinical trial and voluntarily join this follow-up phase. For the first two years, follow-up visits occur every two months, then every six months from year three through five. No new interventions are administered during this follow-up; the study is designed to observe and assess ongoing outcomes. During the study, participants will undergo regular safety monitoring to track any serious or adverse events. Researchers will also evaluate changes in visual acuity, retinal thickness, and the frequency of additional anti-VEGF therapy after the initial EXG102-031 administration. The study lasts up to five years, providing continuous observation of participants' health and vision status.

A Long-term Follow up Study of EXG102-031 in Participants With wAMD